Archive for May, 2009
The Vaccines Development Conference September 23-25 2009 Boston MA, USA
Last Updated on Wednesday, 27 May 2009 09:29 Written by admin Wednesday, 27 May 2009 09:29
The Vaccines Development Conference brings together scientists and industry experts from pharma, biotech, academia and government to share what’s working and not working for them, and to address your key vaccine development challenges and questions.
- Novel Adjuvant Development: Hear current advances in novel adjuvants with discussions and case studies from National Cancer Institute, NIH, Big DNA, Datamonitor and Vical
- Thermostability: Learn formulation strategies from Program for Appropriate Technology in Health (PATH), Stabilitech, and Integrity Bio to improve vaccine stability and enhance access
- Delivery: Uncover the latest vaccine delivery advances and the stabilization, potency testing, and formulation developments associated with needle-free delivery with case studies from Georgia Tech, Aktiv-Dry/University of Colorado, and Program for Appropriate Technology in Health (PATH)
- Analytical Testing: Master the most appropriate and efficient analytical testing methods and techniques to evaluate and analyze your vaccines with case studies from Wyeth Vaccines and Genzyme
- Potency and Immunogenicity Testing: Strategize with Acambis/Sanofi-Pasteur, VirXsys, and BigDNA to uncover strategies for improved vaccine assessment.
- Manufacturing & Process Development: Tap into efficient and comparable manufacturing, scale up, and tech transfer approaches from Immunovaccine Technologies, BigDNA, and NIH.
The Vaccines Development Conference
Posted under Press Releases, USA and Canada | No Comments
qPCR – Quantitive Polymerase Chain Reaction & Transcriptional Profiling
Last Updated on Wednesday, 27 May 2009 08:53 Written by admin Wednesday, 27 May 2009 08:53
With increasing applications in research to provide sensitive quantitative measurements of gene expression, including SNP genotyping, mutation detection and quantification, and gene dosage studies, quantitative polymerase chain reaction technology (qPCR) could soon be the standard for determining the genetic changes in response to a pharmacological agent.
Topic Overview
* Biomarkers clinic
* Increasing through-put
* Solid Phase Gene Expression
* Data Management
* Whole Genome Expression Profiling
Why should you attend this event?
With equipment improving all the time to offer high assay throughput and shorter assay times there has never been a better time to review existing technology, and how it can be applied to research & development in your organisation.
Unique in the market place, the inaugural SMi Quantitative Polymerase Chain Reaction (qPCR) & Transcriptional Profiling conference brings together industry leaders to discuss opportunities, advances in technology and time saving strategies. The agenda is case study led, allowing delegates to benchmark their own research against that of their peers.
The qPCR and Transcriptional Profiling event is exclusively designed for the senior level practitioners from the world’s leading pharmaceutical and biotechnology companies.
This exclusive event consists of world-class keynote addresses, panel discussions and case-study sessions on all aspects of qPCR and Transcriptional Profiling, Biostatistics, increasing through-put, microarrays, microRNA expression and an exclusive Biomarkers Clinic!
Don’t miss out on this unique opportunity to increase your throughput, decrease costs and time and make your qPCR really work for you. Can your company afford not to attend?
qPCR – Quantitive Polymerase Chain Reaction & Transcriptional Profiling
Posted under Europe, Genetics & Pharmacogenetics, Press Releases | No Comments
Clinical Trials Forum, 8th & 9th October 2009, Vienna, Austria
Last Updated on Wednesday, 27 May 2009 08:08 Written by admin Wednesday, 27 May 2009 08:08
How successful are you in patient recruitment and retention? When & how to partner with CROs to achieve greater efficiency in clinical trials?
Now it’s time to focus on strategies and innovations for improving patient recruitment and retention. It is the largest cause of study delays. Join us & understand, when to start when optimizing patient recruitment strategies.
Facing a difficult global operating environment, Pharma companies are looking to consistently increase the CRO efficiency and performance. Learn from first hand experience, how to build and benefit from long-term strategic partnerships with CROs. Reveal the new approaches to CRO selection and relationship management. Benchmark how far & how effective are leading Pharma companies in clinical outsourcing.
This Clinical Trials Forum brings you 20 industry experts from leading Pharma & Biotech companies delivering case studies in 2 streams on the best practices & the latest trends in patient recruitment and clinical partnerships.
Posted under Europe, Press Releases | No Comments
Medical Devices in Europe, 17th & 18th September 2009, Vienna, Austria
Last Updated on Wednesday, 27 May 2009 08:08 Written by admin Wednesday, 27 May 2009 08:05
The European region is composed of a diverse range of markets, all at different stages of development. Many of these markets exhibit fast growth rates, and the region as a whole is expected to grow. The inclusion of new member states into the European Union is opening up markets for medical devices. The member countries adhere to the regulations and rules, increase in standardization and conformity, and funding from the EU resulting in greater capital investments.
Medical devices have become an increasingly important health care area in relation to their impact on health and health care expenditure.
Speakers from leading medical device companies will share their knowledge and experience. Join them in Vienna! You will meet experienced professionals and discuss views on latest challenges and trends for medical devices in Europe.
Medical Devices in Europe, 17th & 18th
Posted under Europe, Press Releases | No Comments
5th Annual Project & Portfolio Management in the Pharmaceutical Industry September 17-18 2009 Vienna, Austria
Last Updated on Wednesday, 27 May 2009 08:10 Written by admin Wednesday, 27 May 2009 07:51
What is a balanced portfolio today? How do we ensure, that it’s going to be a balanced one tomorrow?
In current highly regulated and limited resources environment, it is crucial to understand, how to build an optimal mix of innovative projects within a portfolio, bring them forward quickly and manage them effectively.
Reveal new approaches and tools for portfolio prioritization and project selection. Learn from first hand experience, how to select the best portfolio, measure and improve project & portfolio performance.
This event will bring together the experts from the pharmaceutical industry to benchmark their best practices in executing effective project & portfolio management.
5th Annual Project & Portfolio Management in the Pharmaceutical Industry
Posted under Europe, Press Releases | No Comments
International Swine Flu Conference August 19-21 Washington DC
Last Updated on Wednesday, 27 May 2009 03:05 Written by admin Wednesday, 27 May 2009 03:05
Top leaders and key decision-makers of major companies representing a broad range of industries will meet with distinguished scientists, public health officials, law enforcers, first responders, and other experts to discuss pandemic prevention, preparedness, response and recovery at the 1st International Swine Flu Summit.
At the summit, attendees will be able to draw on first-hand best practices to create the solid business continuity plans that their companies and organizations need in order to prepare for, respond to, and survive a pandemic.
The summit draws on the success of the seven previous Bird Flu summits which featured as speakers several distinguished personalities such as Dr. David Nabarro, the United Nations Coordinator for Avian and Human Influenza, Alex Thiermann of the World Organization for Animal Health (OIE) and Dr. Wenqing Zhang of the WHO Epidemic and Pandemic Alert and Response.
Well-known emergency responders, heads of hospitals from around the world, and hog/swine industry leaders will speak in this summit.
| Topics Include: | |
 |
Country Report & Situations Update
|
|
Surveillance and Data Management
|
|
Preparing Communities Strategies; Local Partnership and Participation
|
|
Delivery of Vaccine and Antiviral Medication
|
|
National Pandemic Influenza Medical Countermeasure
|
|
Socio Economic Impact on Hog/Swine Industry
|
|
Benefit-risk Assessment: Public Health, Industry and Regulatory Perspectives
|
|
Prevention Education Efforts and Risk Communication
|
|
Command, Control and Management
|
|
Emergency Response Management
|
|
Business-Based Planning
|
|
School-Based Planning
|
|
Community-Based Planning
|
http://new-fields.com/isfc/
Posted under North America, Press Releases, Swine Flu Research, USA and Canada | No Comments
TimTec Expands Partnership With Collaborative Drug Discovery Through Publishing Three Additional Libraries on CDD’s Free Public Access Database
Last Updated on Wednesday, 13 May 2009 03:56 Written by admin Wednesday, 13 May 2009 03:56
Last October, TimTec and Collaborative Drug Discovery (CDD) established a collaboration in which CDD’s web-based data management system would host two TimTec Natural Products libraries on their free community Public Access site.  Through this partnership, researchers would be able to register for a free account with CDD allowing them to chemically mine the contents of these TimTec compound libraries using CDD’s powerful, intuitive web-based database software.
TimTec is now offering three more libraries on the CDD Public Access database:
The TimTec ActiTarg-K Kinase Modulators library contains over 6,000 compounds known to inhibit protein kinase activity:
http://www.timtec.net/actitarg-k-kinase-modulators.html
The TimTec OGT Inhibitors Analogs library contains more than 300 compounds analogous to three known O-GlcNAc Transferase inhibiting molecules:
http://www.timtec.net/o-glcnac-transferase-inhibitors.html
Finally, the TimTec resourceful Diversity Set is a general screening collection of drug-like compounds that present most diversified selection from TimTec stock. This screening library contains 10,000 of the most diverse compounds, all complying with the Lipinski Rule of Five:
http://www.timtec.net/diversity-set-10k.html
TimTec’s five databases join more than 25 other databases containing chemical and biological data hosted on CDD Public Access, including:
- 47,000 Ki values for 20,000 compounds against 699 GPCR targets from the NIMH Psychoactive Drug Screening Program at the University of North Carolina
- Over 15,000 compounds with Malaria assay data from 5 public data sources
- 48,818 compounds from the Distributed Drug Discovery (D3) at Indiana University – Purdue University Indianapolis (IUPUI)
- Almost 7,500 compounds with Tuberculosis antibacterial and cell viability information from 4 public data sets and growing thanks to their collaboration with the Bill & Melinda Gates Foundation
About TimTec, LLC.
TimTec LLC. – http://www.timtec.net – is a privately held company located in NewarkDelaware, USA. It was founded in 1995 and began its work in the areas of acquisition and distribution of synthetic organic and natural compounds, custom synthesis, and laboratory equipment to become a full service partner for drug discovery. TimTec has established a global network of thousands of scientists from research centers around the world. The company has developed strong in-house expertise assembling general and targeted library collections for variety of research purposes. International customers include major pharmaceutical, biotech, agricultural, and educational companies and institutions, which use TimTec products for research and development programs.
For more information on TimTec library collections, please contact:
Kay Denisova
Business Development
TimTec LLC
Harmony Business Park Building 301-A
Newark, DE 19711
Tel 302 292 8500
Fax 302 292 8520
info(at)timtec.net
http://www.timtec.net
About Collaborative Drug Discovery, Inc.
Collaborative Drug Discovery, Inc. (CDD) – http://www.collaborativedrug.com – provides web-based software that organizes preclinical research data to help scientists advance new drug candidates more effectively. The CDD database enables scientists to “archive, mine, and collaborateâ€Â® around preclinical chemical and biological drug discovery data through a web-based interface. The software helps distributed research groups to safely store and intelligently analyze small molecule, enzyme, cell and animal bioactivity data accumulated from both low-throughput and high-throughput screens. Unique collaboration features and CDD’s community-oriented approach help unite globally dispersed humanitarian efforts against neglected infectious diseases. Similar collaborative strategies are also rapidly gaining prominence in the commercial arena. CDD offers its industrial-strength database software at a price affordable to academic laboratories, research foundations, and small companies.
For further information please contact:
Barry Bunin, PhD
President & CEO
Collaborative Drug Discovery (CDD)
1633 Bayshore Hwy, Suite 342
Burlingame, CA 94010
info(at)collaborativedrug.com
Posted under Compound Libraries, Diversity Libraries, North America, Press Releases, Targeted Libraries | No Comments
3rd International Symposium on Advances in Synthetic and Medicinal Chemistry
Last Updated on Sunday, 10 May 2009 10:19 Written by admin Sunday, 10 May 2009 10:19
Kiev, Ukraine, August 23 – 27, 2009
ASMC09 in Kiev is being prepared by EFMC (European Federation for Medicinal Chemistry) and ChemBridge Corporation, in the series of events which started with ASCMC04 Moscow followed by ASMC07 St. Petersburg.
Prof. Erick Carreira, ETH Zurich, Switzerland and Dr Scott Biller, Novartis Institutes for BioMedical Research, Cambridge, USA, have kindly accepted to be the Chairmen of the Symposium.
The scientific program of the International Symposium on Advances in Synthetic and Medicinal Chemistry will include:
* 28 invited plenary lectures, presented by highly recognized scientists from academia and the pharmaceutical and biotech industry from Europe, USA and former USSR countries.
* 10 short oral communications which will be selected from submitted abstracts
* poster sessions
The scientific program will be complemented by an attractive cultural program in Kiev.
The topics to be covered during this symposium include:
* New Synthetic Methodologies, Total Synthesis of Natural Products and Heterocyclic Chemistry
* Diversity- and Target-Oriented Synthesis and Chemical Biology
* Medicinal Chemistry and Drug Discovery & Development
The program will also include a commercial exhibition and a half-day Business Mini-Symposium “Small Molecule Screening Libraries in Drug Discovery: Experience and Trendsâ€.
The official language of the symposium is English.
http://www.ldorganisation.com
Drug Discovery and Selection – 45e RICT – Orleans, France, July 1-3, 2009
Last Updated on Sunday, 10 May 2009 09:34 Written by admin Sunday, 10 May 2009 09:34
The upcoming edition of the RICT, the annual symposium of the Société de Chimie Thérapeutique (SCT), will be held in Orléans (France). This prestigious International Conference on Medicinal Chemistry will be organized by the University of Orléans and the Institute of Organic and Analytical Chemistry (ICOA).
Aim of the Symposium
The major change which has occurred in drug discovery during the two last decades has clearly been the tremendous increase in data availability. Years ago, the medicinal chemist relied on very limited information on his compounds provided mainly by pharmacologists. Today, he is in danger of being overwhelmed by the flood of data generated by High Throughput technologies of all kinds, structural and physico-chemical, in vitro and in vivo pharmacology or pharmacokinetics. Even if computer-aided data management is of great assistance during the multiparameter optimization process that will allow going from a hit to a drug candidate, drug design remains an art. More than ever, the training of a medicinal chemist is based on experience and requires multiple confrontations with trial and error. In this regard, while SAR “structure-activity relations†remain specific for a pharmacological target (or family of targets), SPR “structure-properties relationsâ€, such as solubility, permeability, plasma protein binding, metabolism, toxicophores… are generic and can be extrapolated from one series to another. Thus, sharing experiences on SAR and SPR at a precompetitive stage should eventually decrease attrition rates at both clinical and preclinical levels. It is the goal of these 45th RICT in Orleans which, like the 43rd RICT in Lille in 2007, will have as theme “Drug Discovery and Selectionâ€, with a particular spotlight on imaging, to provide a stimulating forum for these exchanges.
More information
To find out more about the topics of the conference, we kindly invite you to visit the symposium website http://www.LDOrganisation.com
Posted under Europe, Europe, Press Releases | No Comments
Clinical Trials in Asia Summit 2009
Last Updated on Sunday, 10 May 2009 09:20 Written by admin Sunday, 10 May 2009 09:20
Determining the prospective strategies for Implementing Clinical trials in India & South Asia – Today’s Hottest Market
18th – 20th May 2009, The Park, New Delhi, India
Â
Key Speakers
• Chandrashekhar Potkar, Director, Medical and Regulatory Affairs, Pfizer, India
• Viraj Rajadhyaksha, Senior Manager, Operations, Planning & Mgmt Clinical Research, Pfizer, India
• Rajesh Karan, Regional Head of Translational Medicine & Scientific Operations, Novartis, India
• Anirban Roy Chowdhury, Clinical Research Manager, AstraZeneca, India
• Subbaraju Sagi, Senior Sales Consultant,Oracle Health Sciences
• Mark Engel, Chairman, Excel PharmaStudies, China
• Celestine Juliet, Project Manager, Cipla
• Krathish Bopanna, Senior Vice President, Acunova
• Nermeen Varawalla, Vice President, Scientific & Medical Affairs, PRA International, London
• Paula Mumby, Director, i3 Pharma Resourcing
• Dan Zhang, CEO, Fountain Medical Development, China
• Dalvin Ni, VP, Fountain Medical Development, China
• Milind Antani, Head-Pharma LifeSciences group, Nishith Desai
• Arun Bhatt, President, Clininvent Research
• Arani Chatterjee, Vice President,
Â
India has all the competitive advantages for conducting clinical trials. As the country is increasingly becoming a favored destination for clinical trials, a gap analysis needs to be done to scale up all resources for clinical trials. This scale up is essential for India to cope with the large global clinical trial projects. It is no coincidence over the last decade or more of economic liberalization, and years of unprecedented growth, that India and parts of South Asia are becoming a preferred clinical research destination for multinational pharmaceutical and biotechnology corporations.
Clinical Trials Summit 2009 will discuss the on-going pressing concerns faced in clinical trials operations, addressing the risks, timeline and budget constraint, whilst effectively tackling key challenges in overcoming trials agreement and site contract negotiation hurdles. This year, the operational element of trial site management, strategic partnership with CROs and SMOs, patient, talent & investigators management will be discussed in order to improve and optimize the overall drug development effectiveness and ROI. Find out how to implement and benefit from electronic data management & monitoring cost effectively. This event will be shared by leading industrial practitioners across the region to promote practical discussions; especially on the know-how to manage needs, variability of different countries and institutions to enhance clinical operational excellence and vigilance. Delegates will have the opportunity to learn, network and benchmark against the global top pharmas and local industry leaders on the best practices in talent, site, budget and performance management in clinical trials. The conference aims to provide a detailed analysis of what it takes to conduct clinical trials from a biopharmaceuticals and vaccines perspective in India and China and also addressing risk/benefit balance, anecdotal experiences of the multinational pharmaceutical industry in India and China, selection and role of CROs, logistics of operations, clinical trials management, government policies (including IPR issues) and pharmacovigilance.
Reasons to register today:
• How can you take advantage of the global market for clinical trials?
• Improving and optimizing site management and overall productivity of clinical operations
• Optimising clinical trials operation effectiveness and ROI through strategic site, patient, data and risk management in the regulated markets
• Identify the data management, CMC supply chain, operational requirements and CRO infrastructure in India and South Asia
• Gaining insights on future forwards of clinical trials and valuing its potential
• Discover how to improve your supplier-client relationships
• Complete trials on schedule and budget by learning to overcome hurdles in investigator/patient recruitment
• What are the issues with off-shoring trials to countries such as India & South Asia? What are the ways to overcome them?
• Explore innovative strategies for outsourcing, what you should be looking for in a CRO?
• Working with limited budget to ensure on time study completion
• Escalating patient recruitment and improving patient retention to save cost and reduce lead-time
• Maximizing trials results through overseas multinational/multi-centric trials
• Avoiding potential pitfalls of trials agreement
• Motivating and managing clinical project teams to improve timeline and progressÂ
Â
Who should attend?
From pharmaceutical, biotech and CRO’s: Directors and Heads of:
• Clinical Research & Development
• Clinical Research Services
• Clinical Operations
• Clinical Data Management
• Clinical IT
• Clinical Trials
• Medical Affairs
• Regulatory Affairs
• Compliance
• Quality Control/Assurance/GCP
• Clinical Study Design
• Safety Surveillance
• Subject Recruitment
• E-Clinical Systems
Â
Location
The Park, New Delhi
15 Parliament Street, New Delhi, 110001
Tel: +91 011 2374 3000 Ext 1902, Fax: +91 11 233629320
Posted under Asia, Asia, Clinical Trials, Press Releases | No Comments
KINAXO’s Cellular Target Profiling® reveals mTOR as a new target of Celebrex
Last Updated on Sunday, 10 May 2009 08:46 Written by admin Sunday, 10 May 2009 08:46
Martinsried, Germany, April 29, 2009 / b3c newswire / - Kinaxo Biotechnologies GmbH has successfully applied its Cellular Target Profiling® technology to identify the protein kinase mTOR as a new cellular target of celecoxib (Celebrex®, Pfizer). Celecoxib is a non-steroidal, anti-inflammatory Cox-2 inhibitor approved for the treatment of osteoarthritis, rheumatoid arthritis and acute pain. In addition, celecoxib’s anti-proliferative effect has earned it a place in numerous clinical trials against several malignancies.
The discovery that celecoxib targets mTOR contributes to a better understanding of the drug’s mode of action and efficacy in cancer patients. mTOR (mammalian target of rapamycin) acts as a central regulator of cell proliferation, cell survival, angiogenesis and cell metabolism. Moreover, mTOR is a key intracellular convergence point for a number of signaling pathways that are abnormally activated in many types of cancer.
As traditional drug development approaches become more and more expensive, drug repositioning has been widely recognized as an opportunity to expand a drug’s therapeutical applications. Here, Cellular Target Profiling® provides a powerful approach to revealing new targets that indicate additional or alternative medical uses for clinically validated or approved drugs. Further information on celecoxib reprofiling (AN3) and similar studies with other small molecules (e.g. profiling of the natural product geldanamycin, AN2) can be downloaded from our website at www.kinaxo.com.
Link to the news release
http://www.b3cnewswire.com/popup.php?id=149
About KINAXO
Kinaxo Biotechnologies GmbH is a privately-held biotechnology company based in Munich/Martinsried, Germany. We offer advanced chemical proteomics and phosphoproteomics services to support lead compound selection, target deconvolution, drug reprofiling, and off-target toxicity assessment. Kinaxo has several ongoing collaborations, including with Boehringer Ingelheim, Johnson & Johnson and Takeda.
Posted under Cancer Research, Drug Development, Europe, Medicinal Chemistry, Press Releases, Proteomics, Targeted Libraries | No Comments
CLC bio’s enterprise platform wins award at Bio-IT World Expo in Boston
Last Updated on Sunday, 10 May 2009 08:32 Written by admin Sunday, 10 May 2009 08:32
Boston, Massachusetts, USA — April 30, 2009 — CLC bio’s enterprise platform for Next Generation Sequencing data analysis, CLC Genomics Server, has just been awarded the “Best of Show†prize at the Bio-IT World Conference & Expo 2009 – an award judged by a team of Bio-IT World magazine editors and leading industry experts.
Bio-IT World Editor-in-Chief Kevin Davies, PhD., comments, “Each year we go through a process where our judging panel debates the technical merits and likely business impact of the different technologies presented at the Best of Show awards. CLC bio’s success this year clearly reflects the importance of the incredibly exciting Next Generation Sequencing space, with a solution that is obviously gaining traction with it’s capabilities to handle the immense data management and analytical challenges required in this area.â€
“Judging on several criteria, such as the importance of the problem being addressed and the elegance of the solution provided, it was clear to the judging panel that CLC Genomics Server, and the flexible plug-in structure it provides, delivers an ideal platform for researchers working with Next Generation Sequencing data.†says M. Michael Barmada, PhD. – member of the “Best of Show†judging panel and Director of the Center for Computational Genetics at the Graduate School of Public Health, University of Pittsburgh. “It’s nice to see complex computational algorithms and routines presented with an elegant interface in a user-friendly way, which lowers the technical barriers for all researchers working with high-throughput sequence data analysis.â€
CLC Genomics Server is CLC bio’s advanced and powerful bioinformatics solution which is built upon a powerful and modern three-tier server architecture, that yields flexible options of executing centralized services, easy integration with other applications and services, powerful database communication and data integration, and secure access control framework and central action logging. Customers already using this enterprise platform, includes J. Craig Venter Institute, Albert Einstein College of Medicine, Veridex, and University of California – Berkeley. Read more about this solution here:
http://www.clcbio.com/index.php?id=1376